Merck Acquires Afferent Pharmaceuticals for $1,250,000,000

  • Feed Type
  • Date
  • Company Name
    Afferent Pharmaceuticals
  • Mailing Address
    2755 Campus Drive San Mateo, CA 94403 USA
  • Company Description
    A leader in the development of novel, selective small molecules that target the P2X3 purinergic receptor, for the treatment of a range of debilitating symptoms and sensory disorders.
  • Website
  • Transaction Type
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
  • M&A Terms
    Under terms of the agreement, Merck, through a subsidiary, will acquire all outstanding stock of Afferent in exchange for an upfront payment of $500 million in cash. Also, Afferent shareholders will be eligible to receive a total of up to an additional $750 million associated with the attainment of certain clinical development and commercial milestones for multiple indications and candidates, including AF-219

Trending on Xconomy